Dyne Therapeutics, Inc.

NasdaqGS:DYN Stock Report

Market Cap: US$2.5b

Dyne Therapeutics Management

Management criteria checks 2/4

Dyne Therapeutics' CEO is John Cox, appointed in Mar 2024, has a tenure of less than a year. directly owns 0.036% of the company’s shares, worth $916.17K. The average tenure of the management team and the board of directors is 3.6 years and 5.2 years respectively.

Key information

John Cox

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.04%
Management average tenure3.6yrs
Board average tenure5.2yrs

Recent management updates

Recent updates

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Nov 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Dyne Therapeutics' Q3 Preview: High-Risk, High-Reward Path In Muscle Diseases

Nov 11

Dyne Therapeutics: Management Merry-Go-Round, Shaky Data Rock Wall Street

Sep 04

Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Aug 14
Companies Like Dyne Therapeutics (NASDAQ:DYN) Are In A Position To Invest In Growth

Dyne Therapeutics: Progress Undenied In DM1 And DMD Trials

May 21

We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

May 04
We're Not Very Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dyne: H2 2024 Muscle Disease Data Could Boost Value

Mar 05

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Aug 09
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

Mar 26
We're Keeping An Eye On Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Rate

We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Dec 10
We Think Dyne Therapeutics (NASDAQ:DYN) Needs To Drive Business Growth Carefully

Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Aug 26
Is Dyne Therapeutics (NASDAQ:DYN) In A Good Position To Invest In Growth?

Dyne wins regulatory nod to start trial for myotonic dystrophy candidate

Jul 12

Dyne stock rises 12% as FDA lifts hold on starting muscle disorder study of DYNE-251

Jul 05

Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 05
Here's Why We're Watching Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

Jan 12
We're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash Wisely

We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Sep 29
We Think Dyne Therapeutics (NASDAQ:DYN) Can Afford To Drive Business Growth

Dyne Therapeutics' chief scientific officer Romesh Subramanian steps down

Jun 02

Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Dyne Therapeutics' (NASDAQ:DYN) Cash Burn Situation

Dyne Therapeutics EPS beats by $0.10

May 06

CEO

John Cox (61 yo)

less than a year

Tenure

Mr. John G. Cox, M.B.A. serves as Chief Executive Officer, President and Director at Dyne Therapeutics, Inc. from March 2024. He also serves as Atlas Advisor at Atlas Venture L.P. since 2024. He serves as...

Leadership Team

NamePositionTenureCompensationOwnership
John Cox
CEO, President & Directorless than a yearno data0.036%
$ 916.2k
Romesh Subramanian
Co-Founder & Advisorno dataUS$4.37mno data
Richard Scalzo
Senior VP and Head of Finance & Administration4.5yrsno data0.0073%
$ 182.9k
John Najim
Chief Technical Officer1.8yrsno datano data
Oxana Beskrovnaya
Chief Scientific Officer3.6yrsUS$1.49m0.035%
$ 885.4k
Amy Reilly
Senior VP and Head of Corporate Communications & Investor Relations4.5yrsno datano data
Daniel Wilson
Senior VP & Head of Legal4.6yrsno datano data
Lucia Celona
Chief Human Resource Officerless than a yearno datano data
Debra Feldman
Chief Regulatory Affairs Officer4.7yrsno datano data
Ashish Dugar
Chief Medical Affairs Officer3.9yrsno datano data
Johanna Friedl-Naderer
Chief Commercial Officerless than a yearno datano data
Douglas Kerr
Chief Medical Officerless than a yearno datano data

3.6yrs

Average Tenure

56.5yo

Average Age

Experienced Management: DYN's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Cox
CEO, President & Directorless than a yearno data0.036%
$ 916.2k
Sudhir Agrawal
Member of Scientific Advisory Boardno datano datano data
Edward Hurwitz
Independent Director6.2yrsUS$250.17k0%
$ 0
David Lubner
Independent Director4.8yrsUS$264.17k0.053%
$ 1.3m
Jason Rhodes
Independent Chairman7.1yrsUS$283.17k0%
$ 0
Dirk Kersten
Independent Director6.2yrsUS$262.67k0%
$ 0
Francesco Muntoni
Member of Scientific Advisory Board4.5yrsno datano data
Louis Kunkel
Member of Scientific Advisory Boardno datano datano data
Nancy Andrews
Member of Scientific Advisory Boardno datano datano data
Catherine Stehman-Breen
Independent Director5.6yrsUS$253.92k0.088%
$ 2.2m
Charles Thornton
Member of Scientific Advisory Boardno datano datano data
Jeffrey Statland
Member of Scientific Advisory Board4.7yrsno datano data

5.2yrs

Average Tenure

61yo

Average Age

Experienced Board: DYN's board of directors are considered experienced (5.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:57
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dyne Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Keay NakaeChardan Capital Markets, LLC
Debjit ChattopadhyayGuggenheim Securities, LLC